Carisma Therapeutics Inc. (CARM)
0.44
-0.01 (-3.25%)
At close: Jan 15, 2025, 10:46 AM
undefined% (undefined)
| Bid | 0.44 |
| Market Cap | 18.47M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.52 |
| PE Ratio (ttm) | -0.29 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.46 |
| Volume | 105,595 |
| Avg. Volume (20D) | 265,568 |
| Open | 0.46 |
| Previous Close | 0.45 |
| Day's Range | 0.44 - 0.48 |
| 52-Week Range | 0.38 - 2.77 |
| Beta | undefined |
About CARM
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collabor...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2014
Employees 107
Stock Exchange NASDAQ
Ticker Symbol CARM
Website https://carismatx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CARM stock is "Hold." The 12-month stock price forecast is $6.5, which is an increase of 1369.59% from the latest price.
Buy 16.67%
Hold 66.67%
Sell 0.00%
Next Earnings Release
Carisma Therapeutics Inc. is scheduled to release its earnings on Mar 31, 2025,
before market opens.
Analysts project revenue of $5.42M, reflecting a 26.37% YoY growth and earnings per share of -0.22, making a -57.69% decrease YoY.
Analysts project revenue of $5.42M, reflecting a 26.37% YoY growth and earnings per share of -0.22, making a -57.69% decrease YoY.
1 month ago ·
Source
-12.82%
Carisma Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
5 months ago ·
Source
+12.62%
Carisma Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
